보호된 글: Assess Commercial Readiness in Europe (draft)
Unlock Opportunities in Europe With EVERSANA
Related Articles
Why Launching in Europe Is Unlike Launching Anywhere Else
Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the […]
WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent
Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This […]
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains […]